ホーム>>PfDHODH-IN-2

PfDHODH-IN-2

カタログ番号GC61177

PfDHODH-IN-2、ジヒドロチオフェノン誘導体 (化合物 11) は、1.11 μM の IC50 を持つ強力な熱帯熱マラリア原虫ジヒドロオロテート デヒドロゲナーゼ (PfDHODH) 阻害剤です。

Products are for research use only. Not for human use. We do not sell to patients.

PfDHODH-IN-2 化学構造

Cas No.: 425629-94-3

サイズ 価格 在庫数 個数
10mM (in 1mL DMSO)
$168.00
在庫あり
5mg
$153.00
在庫あり
10mg
$234.00
在庫あり
25mg
$441.00
在庫あり
50mg
$684.00
在庫あり
100mg
$945.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM. PfDHODH-IN-2 acts as an antimalarial agent and can be used for the research of malaria[1].

Malaria is a global parasitic infectious disease caused by Plasmodium parasites, among which Plasmodium falciparum is the most dangerous one with the highest rates of complications and mortality[1].PfDHODH-IN-2 shows an overall selectivity for PfDHODH (IC50=1.113 µM) over hDHODH (IC50>50 µM). PfDHODH-IN-2 demonstrats in vitro potency against the 3D7 and Dd2 strains of P. falciparum with IC50 values of both >20 µM, respectively in whole cell assays[1].

[1]. Minghao Xu, et al. Novel selective and potent inhibitors of malaria parasite dihydroorotate dehydrogenase: discovery and optimization of dihydrothiophenone derivatives. J Med Chem. 2013 Oct 24;56(20):7911-24.

レビュー

Review for PfDHODH-IN-2

Average Rating: 5 ★★★★★ (Based on Reviews and 11 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PfDHODH-IN-2

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.